TPTX Crosses Above Average Analyst Target
August 22, 2019 at 08:44 AM EDT
In recent trading, shares of Turning Point Therapeutics Inc (TPTX) have crossed above the average analyst 12-month target price of $50.80, changing hands for $52.28/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level..